SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on November 10, 2021. The filing serves to report the Company's financial results for the quarter ended September 30, 2021, as detailed in a press release furnished as Exhibit 99.1. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ATHA.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text. Therefore, no specific financial values can be extracted from this document.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text body. It directs readers to the press release for the specific results of operations and financial condition for the quarter ended September 30, 2021.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The Company utilizes various channels to disclose material information, including its website, investor relations portal, and social media accounts (Twitter, LinkedIn, Facebook). Investors are encouraged to monitor these channels for updates on product candidates and other material matters.
Unusual Items: None are explicitly described in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated November 10, 2021) for specific Q3 2021 financial figures, as they are not present in the 8-K text.
- Verify the Company's status as an Emerging Growth Company and its implications for financial reporting standards.
- Monitor the Company's official social media channels and investor relations website for real-time updates on product candidates.
- Confirm the trading symbol ATHA on the Nasdaq Global Select Market.